Brevo | $582,532,500 | (Dec 5, 2025)
Lumia Security | $18,000,000 | (Dec 5, 2025)
imper.ai | $28,000,000 | (Dec 5, 2025)
Hemab Therapeutics
Denmark
- Copenhagen, Capital Region
- 22/02/2023
- Series B
- $135,000,000
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.
- Industry Biotechnology Research
- Website https://hemab.com/
- LinkedIn https://www.linkedin.com/company/hemabaps/
Related People
Benny SorensenFounder
United States -
Cambridge, Massachusetts
Experienced patient centric Biotechnology Executive with demonstrated translational research, early- intermediate- and late stage clinical development experience. Strong entrepreneurial profile and successful track record of building lean high-performing R&D organizations. Excellent presentation and discussion skills. Extensive pharma-, biotech- and clinical academic high profile network.
IMTC | $12,000,000 | (Dec 5, 2025)
Govstream.ai | $3,600,000 | (Dec 5, 2025)
SPhotonix Inc | $4,500,000 | (Dec 5, 2025)
Unlimited Industries | $12,000,000 | (Dec 5, 2025)
Paradigm Health | $78,000,000 | (Dec 5, 2025)
Guide Labs | $9,000,000 | (Dec 5, 2025)
7AI | $130,000,000 | (Dec 5, 2025)
Ply | $8,500,000 | (Dec 5, 2025)
Find Your Grind | $5,000,000 | (Dec 5, 2025)